Turnstone Biologics (TSBX) Competitors $0.39 -0.02 (-4.40%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$0.39 +0.00 (+0.62%) As of 02/21/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TSBX vs. SRZN, INKT, OKYO, UBX, VYNE, CLDI, ATNM, IRD, GRCE, and PASGShould you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Surrozen (SRZN), MiNK Therapeutics (INKT), OKYO Pharma (OKYO), Unity Biotechnology (UBX), VYNE Therapeutics (VYNE), Calidi Biotherapeutics (CLDI), Actinium Pharmaceuticals (ATNM), Opus Genetics (IRD), Grace Therapeutics (GRCE), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Turnstone Biologics vs. Surrozen MiNK Therapeutics OKYO Pharma Unity Biotechnology VYNE Therapeutics Calidi Biotherapeutics Actinium Pharmaceuticals Opus Genetics Grace Therapeutics Passage Bio Surrozen (NASDAQ:SRZN) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Do institutionals & insiders have more ownership in SRZN or TSBX? 66.6% of Surrozen shares are held by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are held by institutional investors. 43.5% of Surrozen shares are held by insiders. Comparatively, 32.1% of Turnstone Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate SRZN or TSBX? Surrozen presently has a consensus target price of $38.50, suggesting a potential upside of 243.75%. Turnstone Biologics has a consensus target price of $0.45, suggesting a potential upside of 15.80%. Given Surrozen's stronger consensus rating and higher possible upside, research analysts plainly believe Surrozen is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the media prefer SRZN or TSBX? In the previous week, Surrozen's average media sentiment score of 0.00 equaled Turnstone Biologics'average media sentiment score. Company Overall Sentiment Surrozen Neutral Turnstone Biologics Neutral Is SRZN or TSBX more profitable? Turnstone Biologics' return on equity of -105.99% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets SurrozenN/A -120.51% -54.68% Turnstone Biologics N/A -105.99%-87.27% Which has better valuation & earnings, SRZN or TSBX? Surrozen has higher earnings, but lower revenue than Turnstone Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10M3.64-$43.04MN/AN/ATurnstone Biologics$19.31M0.47-$55.20M-$3.24-0.12 Does the MarketBeat Community prefer SRZN or TSBX? Surrozen received 1 more outperform votes than Turnstone Biologics when rated by MarketBeat users. However, 44.44% of users gave Turnstone Biologics an outperform vote while only 25.00% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformSurrozenOutperform Votes525.00% Underperform Votes1575.00% Turnstone BiologicsOutperform Votes444.44% Underperform Votes555.56% Which has more volatility and risk, SRZN or TSBX? Surrozen has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. SummarySurrozen beats Turnstone Biologics on 9 of the 13 factors compared between the two stocks. Get Turnstone Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSBX vs. The Competition Export to ExcelMetricTurnstone BiologicsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.40M$3.12B$5.84B$9.14BDividend YieldN/A1.56%4.76%3.85%P/E RatioN/A13.1718.2614.95Price / Sales0.47269.91434.4770.76Price / CashN/A177.4438.4235.17Price / Book0.093.687.644.65Net Income-$55.20M-$71.72M$3.18B$245.69M7 Day Performance-6.02%-2.46%-1.95%-2.68%1 Month Performance-9.63%-0.25%-0.23%-2.16%1 Year Performance-87.42%-12.31%16.69%12.90% Turnstone Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSBXTurnstone Biologics1.5347 of 5 stars$0.39-4.4%$0.45+15.8%-84.1%$9.40M$19.31M0.0082SRZNSurrozen3.0132 of 5 stars$11.71+9.4%$38.50+228.8%-18.2%$38.06M$10M0.0080INKTMiNK Therapeutics2.4757 of 5 stars$9.50+2.9%$65.00+584.2%+10.7%$37.65MN/A-2.4430News CoverageOKYOOKYO Pharma2.3035 of 5 stars$1.10+2.8%$7.00+539.3%-27.1%$37.05MN/A0.007Analyst ForecastUBXUnity Biotechnology3.8613 of 5 stars$2.19+10.6%$7.33+234.9%+10.9%$36.90M$240,000.00-1.6760Negative NewsVYNEVYNE Therapeutics2.9758 of 5 stars$2.47-0.4%$6.88+178.3%+26.3%$36.43M$420,000.00-2.8730Analyst ForecastNews CoverageCLDICalidi Biotherapeutics2.0033 of 5 stars$1.36+0.7%$16.67+1,125.5%N/A$35.99M$50,000.000.0038Gap UpATNMActinium Pharmaceuticals1.5353 of 5 stars$1.15+4.5%$7.40+543.5%N/A$35.88M$80,000.00-0.8330IRDOpus Genetics1.9573 of 5 stars$1.13-1.7%$8.00+608.0%N/A$35.67M$19.05M-1.0414Analyst ForecastGRCEGrace Therapeutics2.6422 of 5 stars$3.45-0.9%N/AN/A$34.98MN/A-3.42N/AAnalyst ForecastAnalyst RevisionNews CoverageGap DownPASGPassage Bio2.5497 of 5 stars$0.56+7.0%$7.75+1,283.9%-57.7%$34.59MN/A-0.48130News CoverageGap Up Related Companies and Tools Related Companies Surrozen Competitors MiNK Therapeutics Competitors OKYO Pharma Competitors Unity Biotechnology Competitors VYNE Therapeutics Competitors Calidi Biotherapeutics Competitors Actinium Pharmaceuticals Competitors Opus Genetics Competitors Grace Therapeutics Competitors Passage Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TSBX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
